About Us
We are a Canada-based consulting firm that promotes and provides advisory services to clients on innovative medical products and technologies for the prevention and treatment of hard-to-treat cancers and infectious diseases.
The company supports clients through scientific, regulatory, and research-based guidance aimed at advancing safe, effective, and innovative therapeutic solutions.
Mission Statement
Dove Pharmaceutical Consulting Inc. exists to:
- Provide research and development (R&D) guidance in regulatory science and emerging scientific breakthroughs to support the development of safe and effective drugs and biological products.
- Advise clients on alternative therapeutic approaches for late-stage cancers and other serious or terminal diseases where conventional or standard therapies are no longer effective or available.
Research, Experimental Therapies, and Vaccines
Research, Experimental Therapies, and Vaccines
Research, Experimental Therapies, and Vaccines
Proven track record of providing timely advisory on evidence-based R&D for modern therapies for oncology and infectious diseases.
Regulatory guidance for Product Development
Research, Experimental Therapies, and Vaccines
Research, Experimental Therapies, and Vaccines
Providing regulatory guidance to support the development and commercialization of pharmaceuticals, medical technologies, therapies, and vaccines.
Intellectual Property Protection
Research, Experimental Therapies, and Vaccines
Intellectual Property Protection
Extensive expertise in managing intellectual property protection involves safeguarding innovations, technologies, and products through patents, licensing, and confidentiality strategies.
Immunotherapy Products
V-5: Advancing New Frontiers in Liver Cancer Immunotherapy
VJ-3: A clinically safe and effective treatment for ovarian or cervical cancers
V-5: Advancing New Frontiers in Liver Cancer Immunotherapy
V-5 is an innovative oral immunotherapeutic product developed and investigated by Immunitor for its potential application in liver cancer, particularly hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Clinical studies conducted by Immunitor have explored the potential of V-5 as an immune-based approach to supp
V-5 is an innovative oral immunotherapeutic product developed and investigated by Immunitor for its potential application in liver cancer, particularly hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Clinical studies conducted by Immunitor have explored the potential of V-5 as an immune-based approach to support patients with liver cancer. In reported cases, some patients with advanced-stage disease experienced meaningful clinical responses, including significant tumor reduction, disease stabilization, and prolonged survival outcomes.
V-5 represents a novel approach that aims to harness the body’s immune system to recognize and respond to cancer cells. Immunitor’s research has reported encouraging results from clinical investigations, with ongoing efforts focused on further understanding its potential role in improving outcomes for individuals affected by liver cancer.
Through its partnership with Immunitor, Dove Pharmaceutical Consulting Inc., aims to introduce innovative, science-based therapeutic approaches that address unmet needs in cancer care and provide new hope for patients seeking emerging treatment options.
V-7 & MIND: A Natural Approach to Address Mental Illnesses
VJ-3: A clinically safe and effective treatment for ovarian or cervical cancers
V-5: Advancing New Frontiers in Liver Cancer Immunotherapy
Mental illnesses represent one of the greatest public-health pandemics of the modern era.
The use of antidepressants is addictive and can only temporarily relieve the symptoms of mental illnesses. V-7 is drug-free natural product that was designed to treat inflammation in the brain regions that are associated with the genesis of mental disorders.
VJ-3: A clinically safe and effective treatment for ovarian or cervical cancers
VJ-3: A clinically safe and effective treatment for ovarian or cervical cancers
VJ-3: A clinically safe and effective treatment for ovarian or cervical cancers
VJ-3 is a collection of distinct formulations designed and developed by ECG Immunitor to silence the expression of oncogenic (cancerous) genes, and stimulate the body’s natural immunity to recognize and kill cancer cells. In contrast to cancer chemotherapy which can be highly toxic to normal cells and organs, VJ-3 is free of side effects
VJ-3 is a collection of distinct formulations designed and developed by ECG Immunitor to silence the expression of oncogenic (cancerous) genes, and stimulate the body’s natural immunity to recognize and kill cancer cells. In contrast to cancer chemotherapy which can be highly toxic to normal cells and organs, VJ-3 is free of side effects, and can be taken orally without needle injections. In anecdotal studies in many cancer patients, oncologists have documented significant shrinkage of tumor sizes, increase in survival and improved outcomes. VJ-3 has been successfully been used in ovarian/cervical, lung, pancreatic and other cancer patients.
HAP-V+ and HAP-VL to support the recovery/treatment of COVID-19
VJ-3: A clinically safe and effective treatment for ovarian or cervical cancers
VJ-3: A clinically safe and effective treatment for ovarian or cervical cancers
HAP-V+ is a patented oral pill vaccine to support strong immunity, as this is the obvious natural defense to catching colds and/or viral infections, HAP-V+ is today increasingly being used in countries where it is currently available in cases of COVID-19. This supports the extensive anecdotal use reports of people feeling better within as
HAP-V+ is a patented oral pill vaccine to support strong immunity, as this is the obvious natural defense to catching colds and/or viral infections, HAP-V+ is today increasingly being used in countries where it is currently available in cases of COVID-19. This supports the extensive anecdotal use reports of people feeling better within as little as 24 hours when taking HAP-V+ on the first evidence of cold or flu. As reported earlier this year, preliminary tests conducted by a leading Asian university research institute on the Immunitor HAP-V+ Supplement have shown safety and a 90% reduction on SARS-CoV-2 virus infectivity in mammalian cells following exposure to HAP-V+. This laboratory testing highlights HAP-V+ methodology and its potential to inactivate and/or prevent viral infection, and its oral mucosal administration advantage.
Whilst all supplement use feedback and early laboratory results continue to be encouraging, to progress regulatory approval for HAP-V+ as a treatment for COVID-19, influenza, and other respiratory conditions, will still require substantial validation through clinical trials.
Our HAP-VL is designed to treat long COVID symptoms. It reduces prolonged coughing and respiratory distress from long COVID and helps affected organs to recover quicker.
Our Trusted Partners
